According to the new market research report “Infectious Disease Diagnostics Market by Product (Reagents, Kits, Instrument, Software), Test Type (Lab, POC), Disease (COVID-19, Flu, HAIs, HIV, HPV), Technology (Immunodiagnostics, NGS, INAAT, PCR), End User (Hospitals, Labs) – Global Forecast to 2027″, published by MarketsandMarkets™, the market is projected to reach USD 33.1 billion by 2027 from USD 35.5 billion in 2022, at a -1.4% CAGR.
Browse in-depth TOC on “Infectious Disease Diagnostics Market”
164 – Tables
51 – Figures
294 – Pages
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589
Key Market Players
The major players in this market are Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Siemens Healthineers AG (Germany), Danaher Corporation (US), Becton, Dickinson and Company (US), PerkinElmer, Inc. (US), Hologic, Inc. (US), QIAGEN N.V. (Netherlands), Grifols S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), Ortho Clinical Diagnostics Holdings plc (US), Quidel Corporation (US), Meridian Bioscience (US), Genetic Signatures Ltd. (Australia), OraSure Technologies (US), Trinity Biotech Plc. (Ireland), Chembio Diagnostic Systems (US), Seegene, Inc. (South Korea), Co-Diagnostics (US), ELITechGroup (France), Epitope Diagnostics (US), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), InBios International (US), Vela Diagnostics (Singapore) and Uniogen Oy (Finland).
Abbott Laboratories accounted for the largest share of the infectious disease diagnostics market Abbott Laboratories is a leading player in the infectious disease diagnostics market. The launch of the ID NOW POC testing system by the company is expected to support the growth of its infectious disease diagnostics segment. Abbott Laboratories operates through 291 international and 100 domestic subsidiaries and has a strong geographical presence.
F. Hoffmann-La Roche Ltd. accounted for the second largest share of the infectious disease diagnostics market in 2021. Under its flagship brand- cobas- the company offers a wide variety instruments and reagents that are widely used by end users across the globe. The company also has a wide geographic presence, spanning North America, Europe, the Middle East and Africa, and Asia. This enables the company to cater to customers across the globe. Roche Diagnostics mainly focuses on strategic partnerships & acquisitions to maintain its leading position in the market.
Thermo Fisher Scientific accounted for the third largest share of the infectious disease diagnostics market. It is one of the key players operating in the infectious disease diagnostics market. The company’s leading position in this market can be attributed to its strong sales and distribution network, enabling it to effectively market its products in various countries. Thermo Fisher Scientific invests a significant amount of its revenue in R&D. The high R&D investments enable the company to develop and launch new products in the infectious disease diagnostics market. The company adopts inorganic strategies such as acquisitions to maintain its position in this market. For instance, in 2021, the company acquired Mesa Biotech (US) to broaden its POC molecular diagnostics portfolio for infectious diseases.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589
North America is the largest regional market for infectious disease diagnostics market
The infectious disease diagnostic market is segmented into five regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2021, North America accounted for the largest share of the market. The large share of this region can be attributed to the highly developed healthcare system in the US and Canada, the presence of many leading national clinical laboratories, and the easy accessibility to technologically advanced instruments.
Recent Developments
- Roche Diagnostics Launched cobas 5800 system.
- Thermo Fisher Scientific acquired Mesa Biotech (US) to expand the benefits of molecular diagnostics at the point of care.
- Abbott Laboratories launched the ID NOW COVID-19 Test.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=116764589
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
